In December 2014, olaparib was approved in the European Union and United States for the treatment of advanced ovarian cancer with BRCA mutations, this marked the first clinical acceptance of the feasibility of PARP1 as an anti-tumor target and the SL theory. Here, PARP1 is linked to ovarian carcinoma.